396 related articles for article (PubMed ID: 24585509)
21. Interventions for dialysis patients with hepatitis C virus (HCV) infection.
Prabhu AR; Rao IR; Nagaraju SP; Rajwar E; Venkatesh BT; Nair N S; Pai G; Reddy NP; Suvarna D
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007003. PubMed ID: 37096802
[TBL] [Abstract][Full Text] [Related]
22. WITHDRAWN: Ribavirin with or without alpha interferon for chronic hepatitis C.
Gluud LL; Krogsgaard K; Gluud C
Cochrane Database Syst Rev; 2007 Jul; 2002(2):CD002234. PubMed ID: 17636700
[TBL] [Abstract][Full Text] [Related]
23. Ribavirin with or without alpha interferon for chronic hepatitis C.
Kjaergard LL; Krogsgaard K; Gluud C
Cochrane Database Syst Rev; 2002; (2):CD002234. PubMed ID: 12076442
[TBL] [Abstract][Full Text] [Related]
24. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
[TBL] [Abstract][Full Text] [Related]
25. Ribavirin monotherapy for chronic hepatitis C.
Brok J; Gluud LL; Gluud C
Cochrane Database Syst Rev; 2009 Oct; (4):CD005527. PubMed ID: 19821346
[TBL] [Abstract][Full Text] [Related]
26. Ribavirin plus interferon versus interferon for chronic hepatitis C.
Brok J; Gluud LL; Gluud C
Cochrane Database Syst Rev; 2005 Jul; (3):CD005445. PubMed ID: 16034976
[TBL] [Abstract][Full Text] [Related]
27. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials.
Awad T; Thorlund K; Hauser G; Stimac D; Mabrouk M; Gluud C
Hepatology; 2010 Apr; 51(4):1176-84. PubMed ID: 20187106
[TBL] [Abstract][Full Text] [Related]
28. Ribavirin with or without alpha interferon versus no intervention, placebo or alpha interferon for chronic hepatitis C.
Kjaergard LL; Krogsgaard K; Gluud C
Cochrane Database Syst Rev; 2002; (1):CD002234. PubMed ID: 11869633
[TBL] [Abstract][Full Text] [Related]
29. Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B.
Liang N; Kong Z; Ma SS; Lu CL; Yang M; Feng LD; Shen C; Diao RH; Cui LJ; Lu XY; Nikolova D; Jakobsen JC; Gluud C; Liu JP
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD013089. PubMed ID: 30941748
[TBL] [Abstract][Full Text] [Related]
30. The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.
Hartwell D; Cooper K; Frampton GK; Baxter L; Loveman E
Health Technol Assess; 2014 Oct; 18(65):i-xxii, 1-202. PubMed ID: 25350588
[TBL] [Abstract][Full Text] [Related]
31. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman O; Elsayed Z
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
[TBL] [Abstract][Full Text] [Related]
32. Gene therapy for people with hepatocellular carcinoma.
Naing C; Ni H; Aung HH; Htet NH; Nikolova D
Cochrane Database Syst Rev; 2024 Jun; 6(6):CD013731. PubMed ID: 38837373
[TBL] [Abstract][Full Text] [Related]
33. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.
Keating GM; Curran MP
Drugs; 2003; 63(7):701-30. PubMed ID: 12656650
[TBL] [Abstract][Full Text] [Related]
34. Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.
Ugwu EO; Eleje GU; Ugwu AO; Nwagha UI; Ikechebelu JI; Umeh UA; Okafor HU
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013653. PubMed ID: 37306558
[TBL] [Abstract][Full Text] [Related]
35. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
36. Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B.
Liang N; Kong Z; Lu CL; Ma SS; Li YQ; Nikolova D; Jakobsen JC; Gluud C; Liu JP
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD013106. PubMed ID: 31232459
[TBL] [Abstract][Full Text] [Related]
37. Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.
Flori N; Funakoshi N; Duny Y; Valats JC; Bismuth M; Christophorou D; Daurès JP; Blanc P
Drugs; 2013 Mar; 73(3):263-77. PubMed ID: 23436591
[TBL] [Abstract][Full Text] [Related]
38. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
39. Acupuncture for chronic hepatitis B.
Kong Z; Liang N; Yang GL; Zhang Z; Liu Y; Yang Y; Liu YX; Wang QG; Zhang F; Zhang HY; Nikolova D; Jakobsen JC; Gluud C; Liu JP
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD013107. PubMed ID: 31436846
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis.
Mantzoukis K; Rodríguez-Perálvarez M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011645. PubMed ID: 28321877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
